Aslan Fred 4
4 · Artiva Biotherapeutics, Inc. · Filed Aug 18, 2025
Insider Transaction Report
Form 4
Aslan Fred
DirectorPresident and CEO
Transactions
- Tax Payment
Common Stock
2025-05-15$2.13/sh−4,472$9,525→ 412,193 total - Sale
Common Stock
2025-08-15$2.73/sh−25,500$69,579→ 386,693 total - Tax Payment
Common Stock
2025-08-15$2.75/sh−4,472$12,298→ 382,221 total
Footnotes (3)
- [F1]Represents shares withheld by the Issuer to satisfy income tax obligations associated with the vesting of restricted stock unit awards.
- [F2]Represents shares sold pursuant to a Rule 10b5-1 Plan adopted on July 23, 2024, to satisfy income tax obligations associated with the vesting of restricted stock unit awards.
- [F3]The weighted average sale price for the transaction reported was $2.7286, and the range of prices were between $2.60 and $2.80. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided.